Related Experiment Videos
Potential in vitro interaction between tenecteplase and unfractionated heparin
James P Tsikouris1, Christopher P Martin, Craig D Cox
1Schools of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA. james.tsikouris@ttuhsc.edu
Pharmacotherapy
|October 6, 2004
Summary
This study found that tenecteplase may reduce the blood-thinning effects of unfractionated heparin (UFH). This potential drug interaction warrants further clinical investigation for safe anticoagulation management.
Area of Science:
- Pharmacology
- Hematology
- Drug Interactions
Background:
- Unfractionated heparin (UFH) is a widely used anticoagulant.
- Its anticoagulant effect is monitored by activated partial thromboplastin time (aPTT).
- Thrombolytic agents are used to dissolve blood clots.
Purpose of the Study:
- To investigate a potential direct drug interaction between UFH and tenecteplase.
- To determine if tenecteplase reduces the aPTT-prolonging effect of UFH.
Main Methods:
- In vitro experiments using blood samples from healthy volunteers.
- Testing various concentrations of tenecteplase and UFH.
- Comparing aPTT prolongation with UFH alone versus UFH plus tenecteplase.
Main Results:
- Tenecteplase combined with UFH attenuated aPTT prolongation compared to UFH alone.
- Other thrombolytic agents, when combined with UFH, elevated aPTT.
- This suggests a specific interaction between tenecteplase and UFH.
Conclusions:
- A potential drug interaction exists between tenecteplase and UFH in vitro.
- Tenecteplase may attenuate the anticoagulant intensity of UFH.
- Further clinical studies are recommended to validate these findings.